ARDX Ardelyx Inc.

6.53
-0.27  -4%
Previous Close 6.8
Open 6.9
Price To Book 8.71
Market Cap 429,554,129
Shares 65,781,643
Volume 1,030,080
Short Ratio
Av. Daily Volume 765,939
Stock charts supplied by TradingView

NewsSee all news

  1. Ardelyx Announces Pricing of Upsized Public Offering of Common Stock

    FREMONT, Calif., Dec. 4, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with

  2. Ardelyx Announces Proposed Public Offering of Common Stock

    FREMONT, Calif., Dec. 4, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with

  3. Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis

    FREMONT, Calif., Dec. 3, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases,

  4. Ardelyx to Host Conference Call on December 3 to Review Results from the Pivotal Phase 3 PHREEDOM Study

    FREMONT, Calif., Dec. 2, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases,

  5. Ardelyx to Present at the Piper Jaffray 31st Annual Healthcare Conference

    FREMONT, Calif., Nov. 26, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA approval announced September 12, 2019.
Tenapanor (T3MPO-2)
Constipation-predominant irritable bowel syndrome (IBS-C)
Onset of action trial data released November 21, 2017 - noted significantly reduced serum potassium in patients. Development to be discontinued.
RDX7675
Hyperkalemia
Phase 3 data met primary endpoint - December 3, 2019.
Tenapanor - PHREEDOM
Hyperphosphatemia in end-stage renal disease (ESRD) patients
Phase 3 data released May 12, 2017. Primary endpoint met - however, competitive concerns raised.
Tenapanor (T3MPO-1)
Constipation-predominant irritable bowel syndrome (IBS-C)
Phase 3 trial met primary endpoint.
Tenapanor - AMPLIFY
Hyperphosphatemia - adjunctive therapy to phosphate binders

Latest News

  1. Ardelyx Announces Pricing of Upsized Public Offering of Common Stock

    FREMONT, Calif., Dec. 4, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with

  2. Ardelyx Announces Proposed Public Offering of Common Stock

    FREMONT, Calif., Dec. 4, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with

  3. Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis

    FREMONT, Calif., Dec. 3, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases,

  4. Ardelyx to Host Conference Call on December 3 to Review Results from the Pivotal Phase 3 PHREEDOM Study

    FREMONT, Calif., Dec. 2, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases,

  5. Ardelyx to Present at the Piper Jaffray 31st Annual Healthcare Conference

    FREMONT, Calif., Nov. 26, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal

  6. Ardelyx and Kyowa Kirin Expand Partnership with Two Additional Agreements

    FREMONT, Calif. and TOKYO, Nov. 25, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with

  7. Ardelyx Announces Presentation at Kidney Week 2019

    FREMONT, Calif., Nov. 6, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases,

  8. Ardelyx Reports Third Quarter 2019 Financial Results and Recent Highlights

    FREMONT, Calif., Nov. 6, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal

  9. Ardelyx to Host Analyst Day in New York

    FREMONT, Calif., Oct. 10, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), today announced that it will hold an Analyst Day on Thursday, Oct. 17, 2019, from 7:30 a.m. to 11:00 a.m. ET in New York City. This year's

  10. Ardelyx to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    FREMONT, Calif., Sept. 17, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with

  11. Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation

    FREMONT, Calif., Sept. 12, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with

  12. Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment

    FREMONT, Calif., Sept. 3, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal

  13. Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study

    FREMONT, Calif., Sept. 2, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal